Nephrocare Health Services (NEPHROPLUS) Q4 22/23 earnings summary

Executive summary

• FY23 consolidated revenue reached ₹43,729.47 lakh; consolidated loss after tax narrowed to ₹1,178.87 lakh from ₹2,132.66 lakh in FY22.

• Standalone revenue was ₹38,611.08 lakh; audited standalone loss for the year was ₹1,546.49 lakh.

• Management is considering expansion beyond existing operations to improve performance.

Financial highlights

• Consolidated revenue from operations was ₹43,729.47 lakh vs ₹31,766.67 lakh; other income was ₹596.41 lakh vs ₹953.17 lakh.

• Consolidated loss before tax narrowed to ₹859.07 lakh from ₹2,714.05 lakh; loss after tax was ₹1,178.87 lakh vs ₹2,132.66 lakh.

• Consolidated EPS was a loss of ₹67.95 vs a loss of ₹130.96 in FY22; potential equity shares were anti-dilutive.

• Standalone revenue from operations was ₹38,611.08 lakh vs ₹31,690.42 lakh; audited loss before tax was ₹1,287.94 lakh vs ₹2,807.39 lakh.

Outlook and guidance

• Management cited substantial turnover progress and is considering expanding operations beyond current levels to improve performance.